Extraneural ependymoma: distant bone, lung, liver, and lymph node metastases following bevacizumab.

Abstract

Extraneural metastases of ependymoma are rare, and have been reported in the lungs, lymph nodes, pleura, mediastinum, liver, diaphragmatic muscle, and bone. We report a case of anaplastic ependymoma with distant metastases to the vertebral bones, lungs, liver, and lymph nodes following treatment with bevacizumab. Recent research has hypothesized that angiogenic tumors may develop means of resistance to antiangiogenic therapies, and some evidence suggests potential for antiangiogenic therapies to promote additional means for cancer spread. Nevertheless, antiangiogenic therapies continue to demonstrate potential as potent therapies for the treatment of many cancers, and should continue to be researched for future uses.

• Authors: Cheryl Fischer, Sofia S Haque, Jason T Huse, Elen Blochin, Mark M Souweidane, Eric Lis, Yasmin Khakoo
• Journal: Pediatric blood & cancer (Pediatr Blood Cancer) Vol. 60 Issue 1 Pg. 143-5 (Jan 2013) ISSN: 1545-5017 [Electronic] United States
• PMID: 22976578 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012 Wiley Periodicals, Inc.

Chemical References

• Angiogenesis Inhibitors
• Antibodies, Monoclonal, Humanized
• Bevacizumab

Topics

• Angiogenesis Inhibitors (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Bevacizumab
• Brain Neoplasms (drug therapy, pathology)
• Child
• Ependymoma (drug therapy, secondary)
• Female
• Humans
• Liver Neoplasms (secondary)
• Lung Neoplasms (secondary)
• Lymphatic Metastasis
• Spinal Neoplasms (secondary)